Iovance Biotherapeutics Inc
IOVA3.970USD
+0.840+26.84%
Handelsschluss 07/23, 16:00（ET）Kurse um 15 Minuten verzögert
1.33BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Iovance Biotherapeutics Inc Unternehmen
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. It is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its product, Amtagvi, is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. It also develops therapies, such as genetically modified TIL cell therapy and cytokines for use in the TIL cell therapy regimen.
Unternehmensinformationen
BörsenkürzelIOVA
Name des UnternehmensIovance Biotherapeutics Inc
IPO-datumJun 20, 2008
Gegründet am2017
CEODr. Frederick G. Vogt, J.D., Ph.D.
Anzahl der mitarbeiter838
WertpapierartOrdinary Share
GeschäftsjahresendeJun 20
Addresse825 Industrial Road
StadtSAN CARLOS
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94070
Telefon16502607120
Websitehttps://www.iovance.com/
BörsenkürzelIOVA
IPO-datumJun 20, 2008
Gegründet am2017
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
404.60K
+8.00%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
209.85K
+1.45%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
93.63K
+6.91%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Mr. Ryan D. Maynard
Mr. Ryan D. Maynard
Independent Director
Independent Director
7.50K
--
Mr. Matthew W Rosinack
Mr. Matthew W Rosinack
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Wayne P. Rothbaum
Mr. Wayne P. Rothbaum
Independent Director
Independent Director
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Frederick G. Vogt, J.D., Ph.D.
Dr. Frederick G. Vogt, J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
404.60K
+8.00%
Dr. Raj K Puri, M.D., Ph.D.
Dr. Raj K Puri, M.D., Ph.D.
Chief Regulatory Officer
Chief Regulatory Officer
209.85K
+1.45%
Dr. Michael Weiser, M.D., Ph.D.
Dr. Michael Weiser, M.D., Ph.D.
Independent Director
Independent Director
112.63K
--
Dr. Igor P. Bilinsky, Ph.D.
Dr. Igor P. Bilinsky, Ph.D.
Chief Operating Officer
Chief Operating Officer
93.63K
+6.91%
Dr. Iain D. Dukes, Ph.D.
Dr. Iain D. Dukes, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.00K
--
Mr. Daniel Gordon (Dan) Kirby
Mr. Daniel Gordon (Dan) Kirby
Chief Commercial Officer
Chief Commercial Officer
30.00K
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
48.52M
98.37%
Rest of world
804.00K
1.63%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, May 20
Aktualisiert: Tue, May 20
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.30%
MHR Fund Management LLC
7.31%
BlackRock Institutional Trust Company, N.A.
6.15%
Perceptive Advisors LLC
3.81%
Other
66.02%
Aktionäre
Aktionäre
Anteil
Quogue Capital L.L.C.
8.40%
The Vanguard Group, Inc.
8.30%
MHR Fund Management LLC
7.31%
BlackRock Institutional Trust Company, N.A.
6.15%
Perceptive Advisors LLC
3.81%
Other
66.02%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
23.17%
Investment Advisor/Hedge Fund
20.36%
Hedge Fund
12.89%
Private Equity
11.13%
Venture Capital
8.50%
Research Firm
4.03%
Bank and Trust
0.57%
Pension Fund
0.57%
Individual Investor
0.37%
Other
18.39%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
643
273.27M
81.83%
-26.86M
2025Q1
680
275.16M
84.08%
-27.55M
2024Q4
654
278.66M
85.07%
-21.74M
2024Q3
641
272.75M
89.13%
-24.76M
2024Q2
630
269.09M
94.68%
-12.01M
2024Q1
622
253.92M
89.61%
-22.91M
2023Q4
605
240.15M
93.91%
-35.32M
2023Q3
601
248.03M
97.72%
-14.72M
2023Q2
594
232.36M
107.55%
-14.37M
2023Q1
607
232.93M
108.05%
+12.27M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Quogue Capital L.L.C.
28.07M
8.4%
--
--
Apr 17, 2025
The Vanguard Group, Inc.
27.73M
8.3%
+243.44K
+0.89%
Mar 31, 2025
MHR Fund Management LLC
24.42M
7.31%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
20.54M
6.15%
+368.21K
+1.83%
Mar 31, 2025
Perceptive Advisors LLC
12.71M
3.81%
-9.40M
-42.51%
Mar 31, 2025
State Street Global Advisors (US)
11.04M
3.31%
-1.21M
-9.86%
Mar 31, 2025
Long Focus Capital Management LLC
9.25M
2.77%
+4.12M
+80.24%
Mar 31, 2025
Hood River Capital Management LLC
9.22M
2.76%
+224.47K
+2.50%
Mar 31, 2025
Soleus Capital Management, L.P.
7.79M
2.33%
+1.23M
+18.67%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.97M
1.79%
+96.88K
+1.65%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Virtus LifeSci Biotech Products ETF
1.48%
iShares Genomics Immunology and Healthcare ETF
1.06%
WisdomTree BioRevolution Fund
0.53%
SPDR S&P Biotech ETF
0.13%
Direxion Daily S&P Biotech Bull 3X Shares
0.11%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.05%
Strive Small-Cap ETF
0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
Mehr Anzeigen
Virtus LifeSci Biotech Products ETF
Anteil1.48%
iShares Genomics Immunology and Healthcare ETF
Anteil1.06%
WisdomTree BioRevolution Fund
Anteil0.53%
SPDR S&P Biotech ETF
Anteil0.13%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil0.11%
ProShares Ultra Nasdaq Biotechnology
Anteil0.07%
Invesco Nasdaq Biotechnology ETF
Anteil0.06%
iShares Biotechnology ETF
Anteil0.05%
Strive Small-Cap ETF
Anteil0.05%
JPMorgan BetaBuilders US Small Cap Equity ETF
Anteil0.03%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
